Literature DB >> 27757301

Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma.

Nathan B Roberts1, Aniket S Wadajkar1, Jeffrey A Winkles2, Eduardo Davila3, Anthony J Kim4, Graeme F Woodworth1.   

Abstract

Glioblastoma (GBM) is a fatal brain cancer for which new treatment options are sorely needed. Platinum-based drugs have been investigated extensively for GBM treatment but few have shown significant efficacy without major central nervous system (CNS) and systemic toxicities. The relative success of platinum drugs for treatment of non-CNS cancers indicates great therapeutic potential when effectively delivered to the tumor region(s). New insights into the broad anticancer effects of platinum drugs, particularly immunomodulatory effects, and innovative delivery strategies that can maximize these multi-modal effects and minimize toxicities may promote the re-purposing of this chemotherapeutic drug class for GBM treatment.

Entities:  

Keywords:  Carboplatin; cisplatin; glioblastoma; glioblastoma immunosuppression; immunomodulation; immunotherapy; nanomedicine; nanoparticles; oxaliplatin; platinum-based chemotherapy

Year:  2016        PMID: 27757301      PMCID: PMC5048771          DOI: 10.1080/2162402X.2016.1208876

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  78 in total

1.  Local chemotherapy with cisplatin-depot for glioblastoma multiforme.

Authors:  Sergey V Sheleg; Eugeny A Korotkevich; Edvard A Zhavrid; Galina V Muravskaya; Arnold F Smeyanovich; Yury G Shanko; Tatsiana L Yurkshtovich; Pavel B Bychkovsky; Sergey A Belyaev
Journal:  J Neurooncol       Date:  2002-10       Impact factor: 4.130

Review 2.  Nanocarriers for delivery of platinum anticancer drugs.

Authors:  Hardeep S Oberoi; Natalia V Nukolova; Alexander V Kabanov; Tatiana K Bronich
Journal:  Adv Drug Deliv Rev       Date:  2013-10-08       Impact factor: 15.470

3.  A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma.

Authors:  Michael D Prados; S Clifford Schold; Howard A Fine; Kurt Jaeckle; Fred Hochberg; Laszlo Mechtler; Michael R Fetell; Surasak Phuphanich; Lynn Feun; Todd J Janus; Kathleen Ford; William Graney
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

4.  Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles.

Authors:  Xiang-Hong Peng; Yiqing Wang; Donghai Huang; Yuxiang Wang; Hyung Juc Shin; Zhengjia Chen; Michael B Spewak; Hui Mao; Xu Wang; Ying Wang; Zhuo Georgia Chen; Shuming Nie; Dong M Shin
Journal:  ACS Nano       Date:  2011-11-04       Impact factor: 15.881

5.  Targeted delivery of cisplatin by сonnexin 43 vector nanogels to the focus of experimental glioma C6.

Authors:  N V Nukolova; V P Baklaushev; T O Abakumova; P A Mel'nikov; M A Abakumov; G M Yusubalieva; D A Bychkov; A V Kabanov; V P Chekhonin
Journal:  Bull Exp Biol Med       Date:  2014-08-12       Impact factor: 0.804

Review 6.  Mechanisms of immune evasion by gliomas.

Authors:  Cleo E Rolle; Sadhak Sengupta; Maciej S Lesniak
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

7.  Oxaliplatin: a review in the era of molecularly targeted therapy.

Authors:  T Alcindor; N Beauger
Journal:  Curr Oncol       Date:  2011-01       Impact factor: 3.677

Review 8.  Checkpoint blocking antibodies in cancer immunotherapy.

Authors:  Chrisann Kyi; Michael A Postow
Journal:  FEBS Lett       Date:  2013-10-23       Impact factor: 4.124

9.  Encapsulation in nanoparticles improves anti-cancer efficacy of carboplatin.

Authors:  Tanmoy Sadhukha; Swayam Prabha
Journal:  AAPS PharmSciTech       Date:  2014-05-16       Impact factor: 3.246

10.  A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours.

Authors:  R Plummer; R H Wilson; H Calvert; A V Boddy; M Griffin; J Sludden; M J Tilby; M Eatock; D G Pearson; C J Ottley; Y Matsumura; K Kataoka; T Nishiya
Journal:  Br J Cancer       Date:  2011-02-01       Impact factor: 7.640

View more
  6 in total

1.  Harnessing the Potential Synergistic Interplay Between Photosensitizer Dark Toxicity and Chemotherapy.

Authors:  Yan Baglo; Aaron J Sorrin; Barry J Liang; Huang-Chiao Huang
Journal:  Photochem Photobiol       Date:  2020-02-16       Impact factor: 3.421

2.  Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction.

Authors:  Nathan B Roberts; Aymen Alqazzaz; Jacqueline R Hwang; Xiulan Qi; Achsah D Keegan; Anthony J Kim; Jeffrey A Winkles; Graeme F Woodworth
Journal:  J Neurooncol       Date:  2018-08-21       Impact factor: 4.130

3.  miR-152-3p Sensitizes Glioblastoma Cells Towards Cisplatin Via Regulation Of SOS1.

Authors:  Meihua Wang; Qi Wu; Mingming Fang; Wu Huang; Hong Zhu
Journal:  Onco Targets Ther       Date:  2019-11-11       Impact factor: 4.345

4.  Intranasal Administration of Catechol-Based Pt(IV) Coordination Polymer Nanoparticles for Glioblastoma Therapy.

Authors:  Xiaoman Mao; Pilar Calero-Pérez; David Montpeyó; Jordi Bruna; Victor J Yuste; Ana Paula Candiota; Julia Lorenzo; Fernando Novio; Daniel Ruiz-Molina
Journal:  Nanomaterials (Basel)       Date:  2022-04-05       Impact factor: 5.076

Review 5.  Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?

Authors:  Daniel Ruiz-Molina; Xiaoman Mao; Paula Alfonso-Triguero; Julia Lorenzo; Jordi Bruna; Victor J Yuste; Ana Paula Candiota; Fernando Novio
Journal:  Cancers (Basel)       Date:  2022-10-10       Impact factor: 6.575

Review 6.  Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas.

Authors:  Jaewan Jeon; Sungmin Lee; Hyunwoo Kim; Hyunkoo Kang; HyeSook Youn; Sunmi Jo; BuHyun Youn; Hae Yu Kim
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.